PATENT COOPERATION TREATY

PCT

REC'D	0 9	NOA	2005
MISO			PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACT	ION	See Form PCT/IPEA/416	
62446WO (51955)			Priority date (day/month/year)	
International application No.	International filing date (do			
PCT/US04/40403	03 December 2004 (03.12.	2004)	03 December 2003 (03.12.2003)	
International Patent Classification (IPC)		IFC		
IPC(7): A61K 31/55 and US CI.: 514/22	21			
Applicant				
VELA PHARMACEUTICALS, INC.			ished by this International Praiminary	
 This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 				
	a total of sheets, in		sheet.	
 This report is also accomp 	panied by ANNEXES, cor	nprising:		
			sheets, as follows:	
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule				
70.16 and Section 607 of the Administrative Instructions). sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.				
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the				
Administrative I	nstructions).			
4. This report contains indic	cations relating to the follo	wing items:		
Box No. I	Basis of the report		•	
Box No. II F	Priority			
Box No. III Non-establishment of opinion with regard to novelty, inventive step and applicability			ovelty, inventive step and industrial	
Box No. IV I	ack of unity of invention			
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step of industrial applicability; citations and explanations supporting such statement				
Box No. VI	Certain documents cited			
Box No. VII	Certain defects in the inter	national application	l .	
Box No. VIII	Certain observations on the			
Date of submission of the demand		Date of completion	n of this report	
22 June 2005 (22.06.2005)		31 October 2005 (3	1.10.2005)	
Name and mailing address of the IPEA/ US		Authorized officer	•	
Mail Stop PCT, Attn: IPEA/US Commissioner for Patents		Kevin E. Wedding	ton A. Robert's for	
P.O. Box 1450 Alexandria, Virginia 22313-1450			•	
Facsimile No. (703) 305-3230		Telephone No. (57	1) 272-1600	

Form PCT/IPEA/409 (cover sheet)(April 2005)

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.	
PCT/US04/40403	

Во	x No	. I I	Basis of the report			
1.	With	regai	rd to the language, this report is based on:			
	\boxtimes	_	sternational application in the language in which it was filed.			
	a translation of the international application into English, which is the language of a translation furnished for					
	the purposes of:					
	international search (under Rules 12.3 and 23.1(b))					
			publication of the international application (under Rule 12.4(a))			
			international preliminary examination (under Rules 55.2(a) and/or 55.3(a))			
2.	. With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):					
	\boxtimes	the ir	ternational application as originally filed/furnished			
	\bowtie		escription:			
		pages	as originally filed/furnished			
			* NONE received by this Authority on			
	∇					
	M		aims: 8 83-88 as originally filed/furnished			
			* NONE as amended (together with any statement) under Article 19			
			* NONE received by this Authority on			
		page	* NONE received by this Authority on			
	\boxtimes	the d	rawings:			
	K		as originally filed/furnished			
		page	* NONE received by this Authority on			
		page	s* NONE received by this Authority on			
		a seq	uence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.			
3.	\boxtimes	The	emendments have resulted in the cancellation of:			
		\boxtimes	the description, pages NONE			
		\boxtimes	the claims, Nos_NONE			
		$\overline{\boxtimes}$	the drawings, sheets/figs NONE			
		$\overline{\boxtimes}$	the sequence listing (specify): NONE			
		\boxtimes	any table(s) related to the sequence listing (specify):_NONE			
4.		This since	report has been established as if (some of) the amendments annexed to this report and listed below had not been made, they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).			
		\Box	the description, pages			
		Ħ	the claims, Nos			
		Ħ	the drawings, sheets/figs			
		Ħ	the sequence listing (specify):			
		H	any table(s) related to the sequence listing (specify):			
*	If iten	n 4 ap	plies, some or all of those sheets may be marked "superseded."			

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/US04/40403

Box No. V Reasoned statement under Art applicability; citations and exp	ticle 35(2) wit planations sup	h regard to novelty, inventive step or industria porting such statement	J
			
1. Statement			• •
Novelty (N)	Claims	1-21	YES
	Claims	NONE	NO
T	. ·		MEC
Inventive Step (IS)		1-21	YES NO
	Ciainis	NONE	110
Industrial Applicability (IA)	Claims	1-21	YES
•	Claims	NONE	NO
2. Citations and Explanations (Rule 70.7) Claims 1-21 meet the criteria set out in PCT Article	e 33(2) as havin	g novelty in the pharmaceutical art.	<u> </u>
Claims 1-21 meet the criteria set out in PCT Article	e 33(3) as havin	g an inventive step in the pharmaceutical art.	
Claims 1-21 meet the criteria set out in PCT Articl	e 33(4) as havin	g industrial applicability in the pharmaceutical art.	
	_		